mmelvin MedPage Today) — The investigational monoclonal antibody mirikizumab was more effective in inducing and maintaining clinical remission in patients with moderate to severe ulcerative colitis (UC) compared with placebo, according to two phase III…
Read More
We will be happy to hear your thoughts
